Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

Alicia Padilla-Galo, Isabel Moya Carmona,Pilar Ausín, Luis Carazo Fernández,Ismael García-Moguel,José Luis Velasco-Garrido,Rubén Andújar-Espinosa,Francisco Casas-Maldonado,Eva Martínez-Moragón,Carlos Martínez Rivera, Elisabet Vera Solsona, Fernando Sánchez-Toril López, Andrea Trisán Alonso,Marina Blanco Aparicio,Marcela Valverde-Monge, Borja Valencia Azcona, Marta Palop Cervera,Javier Nuevo, Jesús Sánchez Tena, Gustavo Resler, Elisa Luzón, Alberto Levy Naon

Respiratory research（2023）

引用 0|浏览6

暂无评分

摘要

The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain. ORBE II (NCT04648839) was an observational, retrospective cohort study in adult SEA patients who had been prescribed benralizumab. Demographic and clinical data of 204 SEA patients were collected 12 months prior to benralizumab initiation (baseline) and at follow-up. Exacerbation rate, asthma symptoms, maintenance oral corticosteroid (OCS) use and lung function were evaluated, among other variables. A total of 204 SEA patients were evaluated. Mean (standard deviation, SD) age of the study population was 56.4 (12.4) years, 62.3

查看译文

关键词

Benralizumab,Severe eosinophilic asthma,ORBE II,Real world evidence,Biologics,Chronic rhinosinusitis with nasal polyps,Asthma exacerbations,Spain

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要